The burden of invasive pneumococcal disease and the potential for reduction by immunisation

International Journal of Antimicrobial Agents

Volumn 19, Issue 2, 2002, Pages 85-93

  Parsons, Helena K ^a   Dockrell, David H ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Efficacy and cost effectiveness; Immunisation; Incidence; Pneumococcal

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

AGE; AGED; BLOOD CULTURE; CHILD; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INCIDENCE; MORTALITY; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; UNITED STATES;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION; PENICILLIN RESISTANCE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036183180     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00491-5     Document Type: Review

References (96)

1. Bacteraemia, England and Wales: laboratory reports, weeks 46-49/00
2. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis
3. Pneumococcal vaccines WHO position paper
4. Pneumococcal pneumonia: epidemiology and clinical features
5. Invasive pneumococcal disease in England and Wales: vaccination implications
6. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
7. Epidemiology of invasive pneumococcal disease in Southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial
8. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998
9. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children
10. Invasive pneumococcal infection in South and West England
11. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era
12. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population
13. The epidemiology of invasive pneumococcal disease in Alaska 1986-1990: ethnic differences and opportunities for prevention
14. Invasive pneumococcal disease in central Australia
15. The epidemiology of pneumococcal infection in children in the developing world
16. Invasive pneumococcal infection in Baltimore
17. Cigarette smoking and invasive pneumococcal disease
18. Bacteraemic pneumococcal infections in Southern Sweden 1981-96: trends in incidence, mortality, age-distribution, serogroups and penicillin-resistance
19. An outbreak of multi-drug resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents
20. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail
21. A cluster of invasive pneumococcal disease in young children in child care
22. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America
23. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries
24. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants
25. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente
26. Pneumococcal carriage in children in the Netherlands: a molecular epidemiological study
27. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics
28. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children
29. Lobar pneumonia: an occupational disease in welders
30. Reduction in function antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity
31. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries
32. High prevalence of penicillin-nonsusceptible Streptococcus pneumoniae at a community hospital in Oklahoma
33. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis
34. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya
35. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994
36. Epidemiological relation between HIV and invasive pneumococcal disease in San Fransisco County, California
37. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV- seronegative adults
38. Increased risk of bacterial pneumonia in HIV-infected drug users without AIDS
39. Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection
40. Colonization by Streptococcus pneumoniae in human immunodeficiency virus-infected children
41. Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study
42. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
43. Penicillin resistance in laboratory isolates of Streptococcus pneumoniae, in Western Australia, 1990-1994
44. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia
45. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae
46. Clinical significance of pneumococcal bacteraemias in a general hospital: a prospective study 1989-1993
47. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
48. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996. A detailed analysis of 108 cases
49. Early predictors of mortality in pneumococcal bacteraemia
50. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteraemia
51. Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies
52. Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade
53. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention
54. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? The Vaccine Impact Surveillance Network-Invasive Pneumococcal Study Group
55. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an island-wide surveillance study between 1996 and 1997
56. Epidemiology of Streptococcus pneumoniae infection in Malaysia
57. Constancy of distribution of serogroups of invasive pneumococcal isolates among children: experience during 4 decades
58. Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee
59. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)
60. Prevention of pneumococcal pneumonia by vaccination
61. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
62. Pneumococcal vaccine. Efficacy and associated cost savings
63. Influenza and pneumococcal vaccination levels among persons aged > or =65years-United States, 1999
64. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study
65. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people
66. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial
67. Clinical trial of pneumococcal vaccine among institutionalised elderly
68. The clinical effectiveness of pneumococcal vaccination: a brief review
69. Rethinking recommendations for use of pneumococcal vaccines in adults
70. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
71. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study
72. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease
73. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study
74. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine
75. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients
76. 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomised and placebo controlled trial
77. Adult and Adolescent Spectrum of HIV Disease Project: pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination
78. Pneumococcal vaccination: the response of patients with alcoholic liver cirrhosis
79. Radioimmunoassay and opsonic antibody responses to pneumococcal capsular polysaccharide vaccine in serum and ascitic fluid of cirrhotic patients
80. Response to pneumococcal vaccine in renal allograft recipients
81. Effect of immunosuppression after cardiac transplantation in early childhood on antibody response to polysaccharide antigen
82. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation
83. Pneumococcal vaccine response in cirrhosis and liver transplantation
84. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease
85. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
86. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia
87. Immunization of immunosuppressed patients with pneumococcal polysaccharide vaccine
88. A decade (1989-1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice
89. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
90. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine
91. The burden of pneumococcal disease: the role of conjugate vaccines
92. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials
93. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen
94. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly
95. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
96. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European countries